| 1 |
Li SJ,Guo JZ, Zou K, et al. Thromboembolic complications in membranous nephropathy patients with nephritic syndrome-a prospective study [J]. Thromb Res,2012,130(3):501-505.
|
| 2 |
Glassoc RJ. Prophylactic anticoagulation in nephritic syndrome:a clinical conundrum [J]. J Am Soc Nephrol, 2007, 18 (8):2221-2225.
|
| 3 |
Semple JW,Italiano JE Jr,Freedman J. Platelets and the immune continuum [J]. Nat Rev Immunol,2011,11(4):264-274.
|
| 4 |
Scott T,Owens MD. Thrombocytes respond to lipopolysaccharide through Toll-like receptor-4, and MAP kinase and NF-kappa B pathways leading to expression of interleukin-6 and cyclooxygenase-2 with production of prostaglandin E2 [J]. Mol Immunol, 2008, 45(4):1001-1008.
|
| 5 |
Jenne CN, Urrutia R, Kubes P. Platelets: bridging hemostasis,inflammation,and immunity[J]. Int J Lab Hematol,2013,35(3):254-261.
|
| 6 |
Ruggeri ZM,Mendolicchio GL. Adhesion mechanisms in platelet function [J]. Cicr Res,2007,100(12):1673-1685.
|
| 7 |
van Gils JM,Zwagingna JJ,Hordijk PL. Molecular and functional interactions among monocytes,platelets and endothelail cells and their relevance for cardiovascular diseases [J]. J Leukoc Biol,2009,85(2):195-204.
|
| 8 |
Cheng Ck,Chan J,Cembrowski GS,et al. Complete blood count reference interval diagrams derived from NHANES Ⅲ:stratification by age, sex, and race [J]. Lab Hematol,2004,10(1):42-53.
|
| 9 |
Gauer R,Braum MM. Thrombocytopenia [J]. Am Fam Physician,2012,85(6):612-622.
|
| 10 |
Stasi R. How to approach thrombocytopenia. Hematology Am Soc Hematol Educ Program [J]. 2012,2012(1):191-197.
|
| 11 |
Tsai HM. Pathophysiology of thrombotic thrombocytopenic purpura[J]. Int J Hematol,2010,91(2):1-19.
|
| 12 |
Barbour T,Johnson S,Cohney S,et al. Thrombotic microangiopathy and associated renal disorders [J]. Nephrol Dial Transplant,2012,27(7):2673-2685.
|
| 13 |
Sam SS, Syed Omar SF, Teoh BT, et al. Review of dengue hemorrhagic fever fatal cases seen among adults: a retrospective study [J]. PLoS Negl Trop Dis,2013,7(5): e2194.
|
| 14 |
Beshas N,Karpman D,Landau D,et al. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders [J]. Kidney Int,2006,70(3):423-413.
|
| 15 |
Karpman D,Sartz L,Johnson S,et al. Pathophysiology of typical hemolytic uremic syndrome [J]. Semin Thromb Hemost, 2010, 36(6):575-585.
|
| 16 |
Loupiac A,Elayan A,Cailiez M,et al. Diagnosis of streptococcus pneumonia-associated hemolytic uremic syndrome[J]. Pediatr Infect Dis J,2013,32(10):1045-1049.
|
| 17 |
Pelras S,Delmas Y,Lamireau D,et al. Severe transient ADAMTS13 deficiency in pneumococcal-associated hemolytic uremic syndrome[J]. Pediatr Nephrol,2011,26(4):631-635.
|
| 18 |
Kerr H,Richards A. Complement-mediated injury and protection of endothelium: lession from atypical haemolytic uraemic syndrome[J]. Immunobiology,2012,217(2):195-203.
|
| 19 |
Dragon-Durey MA, Loirat C, Cloarec S, et al. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol,2005,16(2):555-563.
|
| 20 |
Tsai HM. Pathophysiology of thrombotic thrombocytopenic purpura.Int J Hematol,2010,91(1):1-19.
|
| 21 |
Ferrari S,Scheiflinger F,Rioger M,et al. Prognostic value of anti-ADAMTS13 antibody features(Ig isotype,titer,and inhibitory effect)in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity[J]. Blood,2007,109(7):2815-2822.
|
| 22 |
Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia [J]. Blood,2011,117(16):4190-4207.
|
| 23 |
Anoop P. Immune thrombocytopenic purpura: historical perspective,current status,recent advances and future directions [J]. Indian Pediatrics,2012,49(10):811-818.
|
| 24 |
Martel N, Lee J, Wells PS, et al. Risk for heparin-induced thrombocytopenia with unfractional and low-molecular-weight heparin thromboprophylaxis: a meta-analysis [J]. Blood, 2005, 106(8):2710-2715.
|
| 25 |
Lo GK,Juhl D,Warkentin TE,et al. Evaluation of pretest clinical score (4T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings [J]. J Thromb Haemost, 2006, 4(4):759-765.
|
| 26 |
Bakchoul T,Greinacher A. Recent advances in the diagnosis and treatment of heparin-induced thrombocytopenia [J]. Ther Adv Hematol,2012,3(4):237-251.
|
| 27 |
Rousan TA, Aldoss IT, Cowley BD, et al. Reccurrent acute thrombocytopenia in the hospitalized patients:sepsis,DIC,HIT,or antibiotic-induced thrombocytopenia [J]. Am J Hematol, 2010, 85(1):71-74.
|
| 28 |
Arnold DM,Nazi I,Warkentin TE,et al. Approach to the diagnosis and management of drug-induced immune thrombocytopenia [J].Transfus Med Rev,2013,27(3):137-145.
|
| 29 |
Bussel JB,Buchanan GR,Nugent dl,et al. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia [J]. Blood,2011,118(1):28-36.
|
| 30 |
Linkins LL, Dans AL, Moores Col LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis,9th ed:American College of Chest Physicians evidence-based clinical practice guidelines [J].Chest,2012,141(2 Suppl): e495S-e530S.
|